NIH Licenses Super Antibodies to Fight Cancer
Published Date: 7/14/2026
Notice
Summary
The National Institutes of Health is offering new, powerful antibodies for licensing that help the immune system fight cancer better by releasing its natural brakes. This opportunity is perfect for companies ready to bring cutting-edge cancer treatments to market faster, with some international patent options available. Interested parties should act soon to explore this exciting tech and start making a difference—and money!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
NIH Antibodies Available for Licensing
The National Institute of Allergy and Infectious Diseases is offering government-owned pan anti-HLA monoclonal antibodies 3C10 and 15B1 for commercial licensing (HHS Ref. E-005-2026-0). A provisional patent application No. 64/053,946 was filed on April 30, 2026, and foreign patent applications have been filed on selected inventions to extend market coverage.
Pre-Clinical Antibodies Show Strong Activity
The pre-clinical antibodies 3C10 and 15B1 bind MHC-I at a different site than earlier antibodies (DX17 and W6/32), bind over 50 times more strongly, and activate human natural killer (NK) and T cells for tumor control. NIAID notes potential uses alone or with other immunotherapies (including CAR-T or CAR-NK) and possible application to chronic infections like TB, HIV, and hepatitis B or C.
Collaboration Opportunity and Contact
NIAID is seeking parties interested in collaborative research to further develop, evaluate, or commercialize this technology and requests statements of capability or interest. To get more information or access unpublished data you must contact Yogikala Prabhu (tel. 202-365-4785, email: Yogikala.Prabhu@nih.gov) and sign a Confidential Disclosure Agreement.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20771, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers seeking funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-20705, Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof
The National Institute of Allergy and Infectious Diseases plans to give Korea National Institute of Health an exclusive license to develop and sell a special antibody that targets a dangerous virus causing severe fever and low platelets. This deal helps speed up turning the invention into real-world treatments. Comments or license requests must be sent by October 26, 2026.
2026-20424, National Cancer Institute; Notice of Meeting
The President's Cancer Panel is holding a free virtual meeting on October 15, 2026, to talk about how GLP-1 medications can help lower cancer risks linked to obesity. Anyone interested can join online or send in comments beforehand. This meeting is a great chance for patients, doctors, and researchers to learn about new ways to fight cancer and improve health.
2026-20365, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings on October 29-30, 2026, to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like biochemistry, software engineering, and mental health will be affected, with no direct money changes announced but important decisions coming soon.
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
Previous / Next Documents
Previous: 2026-14130, Indian Gaming; Approval by Operation of Law of the Wyandotte Nation and State of Kansas Gaming Compact
The Wyandotte Nation and the State of Kansas now have an official gaming agreement that lets the tribe run class III gaming, including sports betting, starting July 14, 2026. Since the government didn’t act within 45 days, the deal automatically got approved by law. This means more gaming options and potential revenue for the tribe and the state, with sports bets placed anywhere in Kansas counting as if made on tribal land.
Next: 2026-14135, David Enright, M.D.; Decision and Order
Dr. David Enright from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.